Nuvectis Pharma, Inc.
NVCT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NVCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NVCT
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology drug candidates, with no approved products or revenue to date.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials for Nuvectis Pharma, Inc..
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology drug candidates, with no approved products or revenue to date.
- Nuvectis has four drug candidates: NXP100, NXP200, NXP900, and NXP800, all in-licensed and in various stages of development [sec_mda · as of 2026-08-04].
- The company has no products approved for sale and has not generated any revenue from product sales [sec_mda · as of 2026-02-11].
- Cash and equivalents were $22.2M as of 2026-06-30, with a net loss of -$7.0M for the same period [sec].
- NXP900 clinical trials include a Phase 1a (started September 2023), Phase 1b single agent (started August 2025), and Phase 1b combination with osimertinib (started December 2025) [sec_mda · as of 2026-08-04].
- The company has not yet completed any pivotal clinical trials or obtained any regulatory approvals [sec_mda · as of 2026-02-11].
What works
- Nuvectis has a pipeline of four in-licensed drug candidates targeting oncology, with NXP900 already in multiple Phase 1 trials [sec_mda · as of 2026-08-04].
- The company has raised capital and executed financing activities to support pipeline development [sec_mda · as of 2026-02-11].
- Management's primary evaluation of success is the ability to progress pipeline assets forward [sec_mda · as of 2025-02-25].
What to weigh
- Nuvectis has no approved products, no revenue from product sales, and has never completed a pivotal clinical trial or obtained regulatory approval [sec_mda · as of 2026-02-11].
- The company is unable to estimate exact working capital requirements due to numerous risks and uncertainties in R&D and commercialization [sec_mda · as of 2026-08-04].
- Future funding requirements depend on many factors including clinical trial outcomes, regulatory review, and manufacturing costs, which could increase significantly [sec_mda · as of 2026-08-04].
From the filings
Quoted directly from source documents.
Nuvectis has no approved products or revenue
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · February 11, 2026
NXP900 clinical trials timeline
“Phase 1a, Phase 1b (single agent) and Phase 1b (combination study with osimertinib) clinical trials for NXP900, which commenced in September 2023, August 2025 and December 2025, respectively.”
SEC MD&A · August 4, 2026
Company has not completed pivotal trials or obtained regulatory approvals
“We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.”
SEC MD&A · February 11, 2026
Risks & what to watch (3)›
Key risks
- No approved products or revenue — Nuvectis has no approved products and no revenue from product sales, with no guarantee of future commercialization [sec_mda · as of 2026-02-11].
- Uncertain funding requirements — Working capital needs are uncertain and could increase significantly due to R&D, regulatory, and manufacturing costs [sec_mda · as of 2026-08-04].
- Clinical and regulatory risks — All candidates are in early stages; failure in trials or regulatory review could halt development [sec_mda · as of 2026-08-04].
What to watch
- Progress and data from NXP900 Phase 1a, Phase 1b single agent, and Phase 1b combination trials [sec_mda · as of 2026-08-04].
- Any updates on regulatory filings with MHRA and FDA for NXP900 [sec_mda · as of 2026-08-04].
- Cash runway and potential need for additional financing given $22.2M cash and ongoing losses [sec].
- Advancement of preclinical candidates NXP100, NXP200, and NXP800 into clinical stages [sec_mda · as of 2026-08-04].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Nuvectis Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nuvectis Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
14.7 months
D/E 1.46 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
62
Total value held
$36.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,319,758 | $10.2M |
| blackrock, inc. | 764,441 | $5.9M |
| iridian asset management llc/ct | 651,757 | $5.0M |
| geode capital management, llc | 384,105 | $3.0M |
| baldwin wealth partners llc/ma | 378,625 | $2.9M |
| state street corp | 166,516 | $1.3M |
| northern trust corp | 124,212 | $960K |
| vanguard fiduciary trust co | 114,842 | $888K |
| susquehanna international group, llp | 105,286 | $814K |
| vanguard portfolio management llc | 92,154 | $712K |
Showing top 10 of 62 institutional holders of Nuvectis Pharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 10.0%
- Days to cover
- 25.5
- Shares short
- 1,541,168
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NVCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Nuvectis Pharma, Inc.?
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology drug candidates, with no approved products or revenue to date.
What is Nuvectis Pharma, Inc.'s lead drug candidate?
Nuvectis Pharma, Inc.'s most advanced tracked candidate is nxp800 (Phase 1) for Advanced Solid Tumor.
Who is the CEO of Nuvectis Pharma, Inc.?
Mr. Ron Bentsur M.B.A. is the chief executive officer of Nuvectis Pharma, Inc. (NVCT).
Where is Nuvectis Pharma, Inc. headquartered?
Nuvectis Pharma, Inc. (NVCT) is headquartered in Fort Lee, NJ, United States.
What therapeutic areas does Nuvectis Pharma, Inc. focus on?
Nuvectis Pharma, Inc. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.